Advocacy in Canada
Over the past few years, an unprecedented number of new treatments became available to Canadian myeloma patients. This progress is thanks to the efforts and collaboration of Myeloma Canada with its industry partners and advocacy groups across the country. There are several ways in which we strive to continue to ensure that the voice of patients is heard.
Did you know?
Sharing the patient perspective is key to influencing recommendations and reimbursement decisions of myeloma treatments by Health Technology Assessment (HTA) agencies such as pCODR and the Institut national d’excellence en santé et en services sociaux (INESSS), and provincial payers. One of the ways we meet this objective is by conducting patient and caregiver surveys to better understand the patient journey and relay valuable information to decision makers.
To participate in patients and caregivers’ surveys, click here to join our mailing list.